BioCentury
ARTICLE | Strategy

Slowing sales growth

December 10, 2001 8:00 AM UTC

Cor Therapeutics Inc.'s cardiovascular drug Integrilin is facing slower sales growth after a quick start. Worldwide Integrilin sales in 2001 are expected to be up 39% compared to 2000, while 2000 Inte...